コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 th acute administration of 10 or 30 mg/kg of morphine sulfate.
2 s rats were given one intra-VTA injection of morphine sulfate (0.0, 0.01, or 0.03 microg, in saline)
3 ; 43 received premedication with intravenous morphine sulfate (0.04 mg per kilogram of body weight) a
4 mg, followed by 10 mg every 5 minutes) with morphine sulfate (2 or 3 mg every 5 minutes) in adult pa
5 ntrolled study using 4 weeks of slow-release morphine sulfate and a corresponding period of matched p
8 intravenous narcotic use (9.2 vs 17.2 mg of morphine sulfate equivalents, P = .03) were significantl
9 rats received 0, 0.6, 1.25, 2.5, or 5 mg/kg morphine sulfate (i.p.) for 4 days, and vehicle only for
10 in areas, 7 additional males received 20 mug morphine sulfate ICV following ethanol injection (ME).
12 ed from noninfected animals and treated with morphine sulfate in vitro produced an increase in the ex
14 thing or a unilateral intra-VTA injection of morphine sulfate (MS) (0.0, 0.01, 0.03, 0.1 or 0.3 micro
15 oliferation, 20 nmol/2 microliters of either morphine sulfate or DAMGO (mu-selective agonist) were ad
16 cted twice daily for a total of 20 days with morphine sulfate or saline beginning at 30 days of age.
18 es including small molecules (norepinephrine-morphine sulfate), protein-protein complexes (insulin-gl
19 mal saline injection, (3) rats injected with MORPHINE sulfate subcutaneously, and (4) rats treated wi
21 he lateral ventricles and 0, 2, 5 micrograms morphine sulfate was administered intracerebroventricula